

Scott Wilkinson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3647293/publications.pdf>

Version: 2024-02-01

14
papers

795
citations

1163117

8
h-index

1125743

13
g-index

23
all docs

23
docs citations

23
times ranked

1830
citing authors

#	ARTICLE	IF	CITATIONS
1	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. <i>Nature</i> , 2019, 576, 465-470.	27.8	510
2	EZH2 inhibition activates a dsRNAâ€“STINGâ€“interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 444-456.	13.2	118
3	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , 2021, 80, 746-757.	1.9	50
4	A case report of multiple primary prostate tumors with differential drug sensitivity. <i>Nature Communications</i> , 2020, 11, 837.	12.8	28
5	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , 2021, 27, 429-437.	7.0	22
6	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. <i>Clinical Cancer Research</i> , 2021, 27, 4836-4847.	7.0	20
7	MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity. <i>Oncogene</i> , 2020, 39, 5663-5674.	5.9	16
8	Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3509-3525.	7.0	11
9	Modeling Androgen Deprivation Therapyâ€“Induced Prostate Cancer Dormancy and Its Clinical Implications. <i>Molecular Cancer Research</i> , 2022, 20, 782-793.	3.4	10
10	Comparison of approaches to transcriptomic analysis in multi-sampled tumors. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	5
11	Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer. <i>Journal of Urology</i> , 2022, 208, 90-99.	0.4	2
12	Battling the two-headed dragon of prostate cancer targeted therapy. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1745037.	0.7	1
13	Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironiâ€™s Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2021.03.009 : Focus on Intraductal Carcinoma of the Prostate. <i>European Urology</i> , 2021, 80, e82-e84.	1.9	1
14	Comment on: Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis by Jing Li etÂ€Aal.. <i>Translational Oncology</i> , 2022, 17, 101347.	3.7	0